Genistein inhibits p38 map kinase activation, matrix metalloproteinase type 2, and cell invasion in human prostate epithelial cells

Cancer Research

Volumn 65, Issue 8, 2005, Pages 3470-3478

  Huang, Xiaoke ^a   Chen, Shan ^a   Xu, Li ^a   Liu, Yueqin ^a,b   Deb, Dilip K ^a,c   Platanias, Leonidas C ^a   Bergan, Raymond C ^a,d  

^a NORTHWESTERN UNIVERSITY   (United States)

^b NATIONAL CANCER INSTITUTE   (United States)

^c UNIVERSITY OF CHICAGO   (United States)

^d NORTHWESTERN UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

4 (4 FLUOROPHENYL) 2 (4 METHYLSULFINYLPHENYL) 5 (4 PYRIDYL)IMIDAZOLE; 4 ETHYL 2 (4 METHOXYPHENYL) 5 (4 PYRIDYL)IMIDAZOLE; GELATINASE A; GENISTEIN; MATRIX METALLOPROTEINASE INHIBITOR; MITOGEN ACTIVATED PROTEIN KINASE P38; MITOGEN ACTIVATED PROTEIN KINASE P38 INHIBITOR; TRANSFORMING GROWTH FACTOR BETA;

ARTICLE; CELL INVASION; CONTROLLED STUDY; DIETARY INTAKE; DRUG EFFECT; DRUG EFFICACY; ENZYME ACTIVATION; ENZYME ACTIVITY; ENZYME INDUCTION; ENZYME INHIBITION; HUMAN; HUMAN CELL; MALE; PRIORITY JOURNAL; PROSTATE EPITHELIUM;

EID: 17144426480     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-04-2807     Document Type: Article

References (50)

1. Severson RK, Nomura AM, Grove JS, Stemmermann GN. A prospective study of demographics, diet, and prostate cancer among men of Japanese ancestry in Hawaii. Cancer Res 1989;49:1857-60.
2. Shimizu H, Ross RK, Bernstein L, et al. Cancers of the prostate and breast among Japanese and white immigrants in Los Angeles County. Br J Cancer 1991;63:963-6.
3. Nabhan C, Bergan RC. Chemoprevention in prostate cancer. In: Bergan RC, editor. Cancer chemoprevention. Boston: Kluwer; 2001. p. 103-36.
4. Clinical development plan: genistein. J Cell Biochem Suppl 1996;26:114-26.
5. Takimoto CH, Glover K, Huang X, et al. Phase 1 pharmacokinetic and pharmacodynamic analysis of unconjugated soy isoflavones administered to individuals with cancer. Cancer Epidemiol Biomarkers Prev 2003;12:1213-21.
6. Fischer L, Mahoney C, Jeffcoat AR, et al. Clinical characteristics and pharmacokinetics of purified soy isoflavones: multiple-dose administration to men with prostate neoplasia. Nutr Cancer 2004;48:160-70.
7. Busby MG, Jeffcoat AR, Bloedon LT, et al. Clinical characteristics and pharmacokinetics of purified soy isoflavones: single-dose administration to healthy men. Am J Clin Nutr 2002;75:126-36.
8. Bloedon LT, Jeffcoat AR, Lopaczynski W, et al. Safety and pharmacokinetics of purified soy isoflavones: single-dose administration to postmenopausal women. Am J Clin Nutr 2002;76:1126-37.
9. Crowell JA, Holmes CJ. Agent identification and preclinical testing. In: Bergan RC, editor. Cancer chemoprevention. Boston: Kluwer; 2001. p. 1-30.
10. Supko JG, Phillips LR. High-performance liquid chromatographic assay for genistein in biological fluids. J Chromatogr B Biomed Appl 1995;666:157-67.
11. Adlercreutz H, Markkanen H, Watanabe S. Plasma concentrations of phyto-oestrogens in Japanese men. Lancet 1993;342:1209-10.
12. Cook LS, Goldoft M, Schwartz SM, Weiss NS. Incidence of adenocarcinoma of the prostate in Asian immigrants to the United States and their descendants. J Urol 1999;161:152-5.
13. Bergan R, Kyle E, Nguyen P, et al. Genistein-stimulated adherence of prostate cancer cells is associated with the binding of focal adhesion kinase to β-1-integrin. Clin Exp Metastasis 1996;14:389-98.
14. Kyle E, Neckers L, Takimoto C, Curt G, Bergan R. Genistein-induced apoptosis of prostate cancer cells is preceded by a specific decrease in focal adhesion kinase activity. Mol Pharmacol 1997;51:193-200.
15. Liu YU, Kyle E, Lieberman R, et al. Focal adhesion kinase (FAK) phosphorylation is not required for genistein-induced FAK-b-1-integrin complex formation. Clin Exp Metastasis 2000;18:203-12.
16. Witkowski CM, Rabinovitz I, Nagle RB, Afflnito KS, Cress AE. Characterization of integrin subunits, cellular adhesion and tumorigenicity of four human prostate cell lines. J Cancer Res Clin Oncol 1993;119:637-44.
17. Liu YQ, Kyle E, Patel S, et al. Prostate cancer chemoprevention agents exhibit selective activity against early stage prostate cancer cells. Prostate Cancer Prostatic Dis 2001;4:81-91.
18. Iishi H, Tatsuta M, Baba M, et al. Genistein attenuates peritoneal metastasis of azoxymethane-induced intestinal adenocarcinomas in Wistar rats. Int J Cancer 2000;86:416-20.
19. Yan C, Han R. Suppression of adhesion-induced protein tyrosine phosphorylation decreases invasive and metastatic potentials of B16-BL6 melanoma cells by protein tyrosine kinase inhibitor genistein. Invasion Metastasis 1997;17:189-98.
20. Yan C, Han R. Genistein suppresses adhesion-induced protein tyrosine phosphorylation and invasion of B16-BL6 melanoma cells. Cancer Lett 1998;129:117-24.
21. Shao ZM, Wu J, Shen ZZ, Barsky SH. Genistein inhibits both constitutive and EGF-stimulated invasion in ER-negative human breast carcinoma cell lines. Anticancer Res 1998;18:1435-9.
22. Penar PL, Khoshyomn S, Bhushan A, Tritton TR. Inhibition of epidermal growth factor receptor-associated tyrosine kinase blocks glioblastoma invasion of the brain. Neurosurgery 1997;40:141-51.
23. Liu Y, Jovanovic B, Pins M, Lee C, Bergan RC. Over expression of endoglin in human prostate cancer suppresses cell detachment, migration and invasion. Oncogene 2002;21:8272-81.
24. Loganadane LD, Vassy J, Legrand C, Fauvel-Lafeve F. Transforming growth factor-β 1 increases the adhesion of MDA-MB-231 mammary adenocarcinoma cells to the microvascular subendothelium. Cell Adhes Commun 1999;7:57-71.
25. Festuccia C, Bologna M, Gravina GL, et al. Osteoblast conditioned media contain TGF-β1 and modulate the migration of prostate tumor cells and their interactions with extracellular matrix components. Int J Cancer 1999;81:395-403.
26. Kostenuik PJ, Singh G, Orr FW. Transforming growth factor β upregulates the integrin-mediated adhesion of human prostatic carcinoma cells to type I collagen. Clin Exp Metastasis 1997;15:41-52.
27. Haves SA, Huang X, Kambhampati S, Platanias LC, Bergan RC. p38 MAP kinase modulates Smad-dependent changes in human prostate cell adhesion. Oncogene 2003;22:4841-50.
28. Stetler-Stevenson WG, Yu AE. Proteases in invasion: matrix metalloproteinases. Semin Cancer Biol 2001;11:143-52.
29. Upadhyay J, Shekarriz B, Nemeth JA, et al. Membrane type 1-matrix metalloproteinase (MT1-MMP) and MMP-2 immunolocalization in human prostate: change in cellular localization associated with high-grade prostatic intraepithelial neoplasia. Clin Cancer Res 1999;5:4105-10.
30. Wood M, Fudge K, Mohler JL, et al. In situ hybridization studies of metalloproteinases 2 and 9 and TIMP-1 and TIMP-2 expression in human prostate cancer. Clin Exp Metastasis 1997;15:246-58.
31. McLaughlin MM, Kumar S, McDonnell PC, et al. Identification of mitogen-activated protein (MAP) kinase-activated protein kinase-3, a novel substrate of CSBP p38 MAP kinase. J Biol Chem 1996;271:8488-92.
32. Derijard B, Raingeaud J, Barrett T, et al. Independent human MAP-kinase signal transduction pathways defined by MEK and MKK isoforms. Science 1995;267:682-5.
33. Rohlff C, Blagosklonny MV, Kyle E, et al. Prostate cancer cell growth inhibition by tamoxifen is associated with inhibition of protein kinase C and induction of p21waf1/cip1. Prostate 1998;37:51-9.
34. Kim IY, Ahn HJ, Zelner DJ, et al. Genetic change in transforming growth factor β (TGF-β) receptor type I gene correlates with insensitivity to TGF-β 1 in human prostate cancer cells. Cancer Res 1996;56:44-8.
35. Kim IY, Ahn HJ, Lang S, et al. Loss of expression of transforming growth factor-β receptors is associated with poor prognosis in prostate cancer patients. Clin Cancer Res 1993;4:1625-30.
36. Kim IY, Ahn HJ, Zelner DJ, et al. Loss of expression of transforming growth factor β type I and type II receptors correlates with tumor grade in human prostate cancer tissues. Clin Cancer Res 1996;2:1255-61.
37. Sehgal I, Baley PA, Thompson TC. Transforming growth factor β1 stimulates contrasting responses in metastatic versus primary mouse prostate cancer-derived cell lines in vitro. Cancer Res 1996;56:3359-65.
38. Sehgal I, Thompson TC. Novel regulation of type IV collagenase (matrix metalloproteinase-9 and -2) activities by transforming growth factor-β1 in human prostate cancer cell lines. Mol Biol Cell 1999;10:407-16.
39. Platanias LC. Map kinase signaling pathways and hematologic malignancies. Blood 2003;101:4667-79.
40. Tong L, Pav S, White DM, et al. A highly specific inhibitor of human p38 MAP kinase binds in the ATP pocket. Nat Struct Biol 1997;4:311-6.
41. Wilson KP, McCaffrey PG, Hsiao K, et al. The structural basis for the specificity of pyridinylimidazole inhibitors of p38 MAP kinase. Chem Biol 1997;4:423-31.
42. Heldin CH, Miyazono K, ten Dijke P. TGF-β signalling from cell membrane to nucleus through SMAD proteins. Nature 1997;390:465-71.
43. Massague J. TGFβ signaling: receptors, transducers, and Mad proteins. Cell 1996;85:947-50.
44. Chen F, Weinberg RA. Biochemical evidence for the autophosphorylation and transphosphorylation of transforming growth factor β receptor kinases. Proc Natl Acad Sci U S A 1995;92:1565-9.
45. Takimoto CH. Basic pharmacokinetics and pharmacodynamic principals. In: Bergan RC, editor. Cancer Chemoprevention. Boston: Kluwer; 2001. p. 85-102.
46. Adlercreutz H. Western diet and western diseases: some hormonal and biochemical mechanisms and associations. Scand J Clin Lab Invest 1990;50 Suppl 201:3-23.
47. Pfohler C, Fixemer T, Jung V, et al. In situ hybridization analysis of genes coding collagen IV α1 chain, laminin β1 chain, and S-laminin in prostate tissue and prostate cancer: increased basement membrane gene expression in high-grade and metastatic lesions. Prostate 1998;36:143-50.
48. Lee JC, Laydon JT, McDonnell PC, et al. A protein kinase involved in the regulation of inflammatory cytokine biosynthesis. Nature 1994;372:739-46.
49. Akiyama T, Ishida J, Nakagawa S, et al. Genistein, a specific inhibitor of tyrosine-specific protein kinases. J Biol Chem 1987;262:5592-5.
50. Overall CM, Lopez-Otin C. Strategies for MMP inhibition in cancer: innovations for the post-trial era. Nat Rev Cancer 2002;2:657-72.